Table 2.

Sensitivity Analysis of OS and PFS for TACE+D+C group vs. TACE+D group (TACE+D as reference group).

Time	Group	Unadjusted HR (95%CI)	P-value	Adjusted* HR (95%CI)	P-value
OS	TACE+D a
OS	TACE+D+C	0.65 (0.45-0.94)	0.025	0.35 (0.22-0.54)	<.001
PFS	TACE+D a
PFS	TACE+D+C	0.57 (0.39-0.83)	0.003	0.34 (0.21-0.53)	<.001

*Full covariates: Age, sex, Child-Pugh class, HBV, portal vein invasion, BCLC stage, albumin, AST, ECOG PS, PIVKA-II, AFP level, tumor size, number of lesions, number of TACE.

^aAs a reference group for adjusting covariates. HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, Progression-free survival; TACE+D, Transarterial Chemoembolization combined with donafenib; TACE+D+C, Transarterial Chemoembolization combined with donafenib and camrelizumab; PSM, propensity score matching.